ACE and heart failure: The RALES (Randomized Aldactone Evaluation Study) showed that SP added to ACE inhibitor therapy reduces the risk of sudden cardiac death (SCD) in patients with severe heart failure and a reduced left-ventricular ejection fraction [15,23].